PFIZER INC — 13F Holdings & Portfolio
CIK 78003 · latest 13F-HR filed 2026-05-12
PFIZER INC manages $238.8M in 13F-reported U.S. long-equity assets across 21 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ORIC (24.14%), ALLO (20.85%), ARVN (14.63%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 1, added to 7, and trimmed 9.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$238.8M
Long-equity book
21
Distinct positions
2026-03-31
Filed 2026-05-12
+1 / −1 / ↑7 / ↓9
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALLOGENE THERAPEUTICS INC$19.6M +65.0%
- ORIC PHARMACEUTICALS INC$13.7M +31.1%
- ZURA BIO LTD$1.3M +8.2%
- PYXIS ONCOLOGY INC$1.1M +13.9%
- CARIBOU BIOSCIENCES INC$891.2K +11.9%
Top Trims
- WAVE LIFE SCIENCES LTD-$19.9M -62.6%
- ARVINAS INC-$6.1M -14.8%
- CELCUITY INC-$3.5M -10.1%
- CARDIFF ONCOLOGY INC-$3.0M -44.8%
- BIOHAVEN LTD-$1.5M -25.9%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $57.7M | 24.14% | 4,780,401 | SH |
| 2 | ALLOGENE THERAPEUTICS INC | ALLO | 019770106 | $49.8M | 20.85% | 22,032,040 | SH |
| 3 | ARVINAS INC | ARVN | 04335A105 | $34.9M | 14.63% | 3,457,815 | SH |
| 4 | CELCUITY INC | CELC | 15102K100 | $31.3M | 13.13% | 295,652 | SH |
| 5 | ZURA BIO LTD | ZURA | G9TY5A101 | $16.8M | 7.05% | 2,838,913 | SH |
| 6 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $11.9M | 5.00% | 1,875,000 | SH |
| 7 | CARIBOU BIOSCIENCES INC | CRBU | 142038108 | $8.3M | 3.50% | 4,690,431 | SH |
| 8 | PYXIS ONCOLOGY INC | PYXS | 747324101 | $7.8M | 3.27% | 5,952,263 | SH |
| 9 | SPERO THERAPEUTICS INC | SPRO | 84833T103 | $5.5M | 2.31% | 2,362,348 | SH |
| 10 | BIOHAVEN LTD | BHVN | G1110E107 | $4.2M | 1.77% | 505,645 | SH |
| 11 | CARDIFF ONCOLOGY INC | CRDF | 14147L108 | $3.7M | 1.57% | 2,411,575 | SH |
| 12 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $2.0M | 0.84% | 953,834 | SH |
| 13 | PYXIS ONCOLOGY INC | PYXS | 747324101 | $1.4M | 0.59% | 1,080,507 | SH |
| 14 | NEXTCURE INC | NXTC | 65343E207 | $1.3M | 0.53% | 127,568 | SH |
| 15 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $813.8K | 0.34% | 75,000 | SH |
| 16 | Q32 BIO INC | QTTB | 746964105 | $736.7K | 0.31% | 101,618 | SH |
| 17 | NEXTCURE INC | NXTC | 65343E207 | $258.1K | 0.11% | 25,786 | SH |
| 18 | BOLT BIOTHERAPEUTICS INC | BOLT | 097702203 | $137.1K | 0.06% | 31,305 | SH |
| 19 | GINKGO BIOWORKS HOLDINGS INC | DNA | 37611X209 | $15.9K | 0.01% | 2,681 | SH |
| 20 | SENSEONICS HLDGS INC | SENS | 81727U105 | $14.2K | 0.01% | 2,171 | SH |
| 21 | GINKGO BIOWORKS HOLDINGS INC | DNA | 37611X209 | $1.5K | 0.00% | 247 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-12 | $238.8M | 21 | 0000078003-26-000064 |
| 2025-12-31 | 2026-02-12 | $236.5M | 21 | 0000078003-26-000013 |
| 2025-09-30 | 2025-11-13 | $437.5M | 24 | 0000078003-25-000161 |